March 30, 2017
Tainan-headquartered ScinoPharm Taiwan (1789, TaiEx), the country’s leading API manufacturer, will continue its strategy of producing high barrier-to-entry API while vertically expanding its offering to encompass the manufacturing of finished injectable products, reported Chen Yung-fa, ScinoPharm’s President & CEO in a recent interview with PharmaBoardroom. Another growth driver for 2017 will be the company’s “Double A” strategy, being API and ANDA, where ScinoPharm is teaming up with pharmaceutical companies to jointly apply for ANDA filing in the US and Europe and export final drug products globally.
“Overall, ScinoPharm can be considered an API leader that is transforming itself into a full-scope specialty pharma, fully leveraging its core competencies in R&D and cGMP manufacturing of high-entry barrier APIs,” reported Chen.
Read the full interview at Pharmaboardroom (free registration required).